Breaking A New 52 Week High, BIO-TECHNE Corp (Nasdaq:TECH) Close At $211.24

TECH
TECH

BIO-TECHNE Corp (Nasdaq:TECH)

June 13th, 2019

Amidst rising markets BIO-TECHNE Corp finished Thursday’s trading session down 1.94%, a ($4.19) decrease to close on $211.24. Despite the drop in price it hit a new 52 week high of $216.47.

TECH was outperformed by the rest of the Healthcare sector which went down just -0.11%.

Forecasts from 8 analysts indicates that BIO-TECHNE Corp might grow somewhat (1.11%), while Finbox has calculated (with medium uncertainty) a fair value price of $167.57.

Market Sectors

The market sectors were mixed Thursday with a majority of the sectors trending up. Energy saw the biggest increase of the day (1.25%), while the Healthcare sector saw the biggest drop (-0.11%). Information Technology has seen the biggest year-to-date gain of 23.06%.

Utilities saw the biggest turn-around compared to its 5-day performance (-0.31%), as it went up by 0.15%. Healthcare saw a turn-around from its 5-day performance of 2.18% trading down -0.11%.

Sector Breakdown

  • Energy, up 1.25%.
  • Communication Services, up 1.14%.
  • Consumer Discretionary, up 0.90%.
  • Materials, up 0.58%.
  • Industrials, up 0.54%.
  • Financials, up 0.23%.
  • Information Technology, up 0.22%.
  • Utilities, up 0.15%.
  • Consumer Staples, up 0.11%.
  • Real Estate, up 0.09%.
  • Healthcare, down -0.11%.

BIO-TECHNE Corp Info

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment offers Biologics tools for researchers to interrogate protein purity and identify contaminants during the development and production of biologics; Western blot, an assay for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment provides blood chemistry and gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market. Bio-Techne Corporation has a strategic cooperation agreement with Micropoint Bioscience; and a strategic collaboration agreement with Elpiscience Biopharmaceuticals Co., Ltd. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. It has strategic partnership with NanoString Technologies. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

All amounts in USD unless otherwise indicated

TECH daily update
TECH daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.

This site uses Akismet to reduce spam. Learn how your comment data is processed.